Wu: She had been tweeting about this, and I knew she would supply some actually balanced perspective right here. First issues first: She has gotten the vaccine. There’s actually no undoing that. However she’s not spending all of her time worrying about getting a clot—partly as a result of that gained’t have an effect on whether or not or not she does—but in addition as a result of these instances have to date been actually, actually uncommon. I don’t assume we but have sufficient info to say they’re going to seem in precisely X proportion of individuals, nevertheless it’s in all probability going to be an awfully low quantity.
Higgins: What are the signs to search for in that very uncommon case?
Wu: There’s an inventory that the CDC and FDA put out. They mentioned in the event you develop extreme complications, belly ache, leg ache, or shortness of breath inside three weeks of your injection, attain out to your health-care supplier. However that’s going to be the following stage up from the anticipated unwanted effects that some folks would possibly get throughout the first couple of days after getting their injection, which could embrace a light headache. So there’s a bit of little bit of subjectivity there, however hopefully individuals are simply protecting a watch out in these three weeks. That’s the crucial window we’re taking a look at right here.
Hamblin: Do you assume this has been dealt with appropriately? Do you assume pausing Johnson & Johnson for everybody was the suitable transfer?
Wu: That’s a tough query to reply, however I feel I lean on the facet of “sure.” Think about if the CDC and FDA had waited till it was 20 instances, or 30 instances, or 100 instances … [they] would have gotten questions on why they didn’t pause it when it was simply six and we might have prevented 94 extra instances.
I feel they noticed a sign and never only a random cluster of blood clots [that] all regarded so related on this demographic slice of the inhabitants. And they also acted shortly. This pause might simply be a matter of days to get readability and be sure that individuals are conscious and searching for it. I wouldn’t be stunned if extra instances come up as a result of we now know to search for it. [But] they don’t seem to be hoping to completely derail this vaccine.
Hamblin: Do you assume this pause—assuming it doesn’t pan out to be over a significant danger issue and Johnson & Johnson will get again on-line—will, over time, result in vaccine hesitancy of the type that we’ve seen with AstraZeneca in Europe? How involved are you about it exacerbating what we’ve already seen within the U.S.?
Wu: I’m involved about this, however I don’t need to soar to conclusions about how hesitancy will likely be affected. It’s so difficult as a result of exacerbating hesitancy can happen in a mess of the way. One is: Individuals hear one thing adverse concerning the vaccine and so they really feel much less good about taking it. One other is that consultants conceal one thing concerning the vaccine and the general public seems like they’re not being trusted with the related info.
The CDC and FDA are in a little bit of a “damned in the event you do, damned in the event you don’t” state of affairs, however I’ve been actually impressed with how quite a lot of consultants have tried to speak the state of affairs as clearly as they’ll, and actually stress the purpose that we will make better-informed selections with this info being publicly on the market.